FL-MHPS
15.4.2020 12:02:05 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems’ (MHPS) J-Series gas turbine installed fleet today reached one million hours of commercial operation, nearly double that of similar sized gas turbines from competitors. This gas turbine series — the company’s largest and most advanced — leads the industry with reliable, efficient power generation and flexibility to meet rigid new standards for reduced carbon emissions. Introduced in 2011, the J-Series delivers an industry-leading overall reliability of 99.5% and an efficiency greater than 64%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005220/en/
Forty-three J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
Donald Schubert, Principal at SHL Consulting LLC and former Senior Vice President of Marshes Global Power Practice, said, “MHPS continues to embrace proven technology throughout their gas turbine fleet. The insurability of the operating units remains at an all-time high for MHPS large frame machines.”
In many parts of the world, the J-Series gas turbine frequently replaces retired coal-fired power generation or is installed as an alternative to coal-fired power generation. Compared to the same size coal-fired power plants, one million J-Series operating hours has resulted in CO2 emissions reduction of 270 million tons. This is equivalent to CO2 emissions from 1,346,918 railcars of coal burned.
Ken Kawai, President and CEO of MHPS said, “As we reflect on the important milestone of achieving one million operating hours with our J-Series gas turbine, we know the most important part of that accomplishment is that we ran all those hours with 99.5% reliability. It all started with T-Point, our own combined cycle power plant in Takasago, Japan. Our extreme reliability is not by good luck. It is because we test the durability and reliability of every new technological advancement for 8,000 hours before shipping it to our customers. We have now built a second T-Point, T-Point 2, where our latest advancement, the cutting-edge air-cooled 60 Hz JAC, has just synced to the grid and achieved full load. Step-by-step, we have developed the largest, most reliable and most fuel-efficient gas turbine in the world.”
Recent innovations to the J-Series target further reductions in carbon emissions. Last month the company received an order from the Intermountain Power Agency, in Delta, Utah, for two JAC gas turbines capable of using up to 30% renewable hydrogen fuel. Eventually, these turbines will be capable of using 100% renewable hydrogen fuel. The 30% hydrogen system will reduce carbon emissions by more than 75% compared to the same size coal-fired power plant, and the 100% hydrogen system will eliminate carbon emissions entirely. MHPS is also developing grid-scale renewable hydrogen production and storage through the Advanced Clean Energy Storage (ACES) project in Delta, Utah.
Paul Browning, President and CEO of MHPS Americas and newly appointed Chief Regional Officer for Europe, Africa and the Middle East, said, “Going forward, every gas turbine MHPS sells globally will have renewable hydrogen fuel capability. This allows our customers to purchase a natural gas power plant today, and convert it over time into a renewable energy storage facility. This gives plant operators flexibility now and into the future to choose what mix of natural gas power generation and renewable energy storage best meets the needs of their electrical grids. We are providing the power generation and storage solutions that enable our customers to combat climate change and advance human prosperity. This is a Change in Power.”
About Mitsubishi Hitachi Power Systems Americas, Inc. Mitsubishi Hitachi Power Systems Americas, Inc. (MHPS Americas), headquartered in Lake Mary, Florida, employs more than 2,000 power generation and energy storage experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity. MHPS Americas’ expertise includes natural gas, steam, aero-derivative, geothermal, and distributed renewable power generation technologies and services, along with renewable hydrogen and battery energy storage systems, environmental control systems solutions, and digital solutions enabling autonomous operations and maintenance of power assets throughout North and South America. MHPS Americas is a subsidiary of Mitsubishi Hitachi Power Systems (MHPS), a joint venture between Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in power generation systems. Learn more about MHPS by visiting www.changeinpower.com . |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom